Day, T. A., Penn-Nicholson, A., Luabeya, A. K. K., Fiore-Gartland, A., Du Plessis, N., Loxton, A. G., Vergara, J., Rolf, T. A., Reid, T. D., Toefy, A., Shenje, J., Geldenhuys, H., Tameris, M., Mabwe, S., Bilek, N., Bekker, L., Diacon, A., Walzl, G., Ashman, J., Frevol, A., Sagawa, Z. K., Lindestam Arlehamn, C., Sette, A., Reed, S. G., Coler, R. N., Scriba, T. J., Hatherill, M., , , Beckmann, A. M., Hsu, F., Albertson, S., Veldsman, A., Schreuder, C., Smit, E., Cloete, Y., Ontong, C., Filander, E., Jacobs, G., Keyser, A., Africa, H., Mulenga, H., Noble, J., Makhethe, L., Steyn, M., de Kock, M., Quaqua, N., Lu, Y., Gutschmidt, A., Thienneman, F., Kahn, S., Mouton, A., Van Rooyen, E., Opperman, F., Swarts, A., Van Schalkwyk, A., Herselman, Y., Hofmeester, D., Amsterdam, J., Hassanally, L., van der Merwe, L., Companie, A., Rossouw, S., Jones, C., Botes, N., van der Riet, E., Goliath, S., Kruger, S., & Sinandile, E. (2021). safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet, 9(4), 373–386. http://access.bl.uk/ark:/81055/vdc_100124368006.0x000017